Core Viewpoint - The stock of Cornerstone Pharmaceuticals-B (02616) has seen an increase of over 3%, currently trading at 6.99 HKD with a transaction volume of 15.38 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO conference in 2025 [1] Group 1: Clinical Pipeline Updates - Cornerstone Pharmaceuticals is set to present preliminary data from its core clinical pipeline, specifically the CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody) and CS5001 (a ROR1 antibody-drug conjugate) at the 2025 ESMO annual meeting [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, fulfilling ESMO's submission requirements [1] - At the ESMO conference, Cornerstone will showcase preliminary data from the I phase dose-escalation study of CS2009 involving approximately 70 patients with advanced solid tumors, marking the first known clinical data presentation globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1]
港股异动 | 基石药业-B(02616)涨超3% 将于ESMO大会上公布PD-1/VEGF/CTLA-4三抗I期剂量递增临床数据